| Serial Number | 90700876 |
| Word Mark | SYNTHETIC BIOPSY |
| Filing Date | Monday, May 10, 2021 |
| Status | 700 - REGISTERED |
| Status Date | Tuesday, February 13, 2024 |
| Registration Number | 7305215 |
| Registration Date | Tuesday, February 13, 2024 |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, July 26, 2022 |
| Goods and Services | Medical products for human use that trigger expression or activation in the human body of a biomarker, compound or body response useable for prevention of diseases, namely, cancer or other diseases related to genetic dysregulation; Medical products for human use that trigger expression or activation in the human body of a biomarker, compound or body response useable for detection of diseases, namely, cancer or other diseases related to genetic dysregulation; Medical products for human use that trigger expression or activation in the human body of a biomarker, compound or body response useable for localization of diseases, namely, cancer or other diseases related to genetic dysregulation; Medical products for human use that trigger expression or activation in the human body of a biomarker, compound or body response useable for therapy of diseases, namely, cancer or other diseases related to genetic dysregulation; Medical products for animal use that trigger expression or activation in the animal body of a biomarker, compound or body response useable for prevention of diseases, namely, cancer or other diseases related to genetic dysregulation; Medical products for animal use that trigger expression or activation in the animal body of a biomarker, compound or body response useable for detection of diseases, namely, cancer or other diseases related to genetic dysregulation; Medical products for animal use that trigger expression or activation in the animal body of a biomarker, compound or body response useable for localization of diseases, namely, cancer or other diseases related to genetic dysregulation; Medical products for animal use that trigger expression or activation in the animal body of a biomarker, compound or body response useable for therapy of diseases, namely, cancer or other diseases related to genetic dysregulation |
| Goods and Services | Medical services for prevention of diseases in humans based on technology focused on triggering the expression or activation in the human body of a biomarker, compound or body response usable for these medical services; Medical services for detection of diseases in humans based on technology focused on triggering the expression or activation in the human body of a biomarker, compound or body response usable for these medical services; Medical services for localization of diseases in humans based on technology focused on triggering the expression or activation in the human body of a biomarker, compound or body response usable for these medical services; Medical services for therapy of diseases in humans based on technology focused on triggering the expression or activation in the human body of a biomarker, compound or body response usable for these medical services; Medical services for prevention of diseases in animals based on technology focused on triggering the expression or activation in the animal body of a biomarker, compound or body response usable for these medical services; Medical services for detection of diseases in animals based on technology focused on triggering the expression or activation in the animal body of a biomarker, compound or body response usable for these medical services; Medical services for localization of diseases in animals based on technology focused on triggering the expression or activation in the animal body of a biomarker, compound or body response usable for these medical services; Medical services for therapy of diseases in animals based on technology focused on triggering the expression or activation in the animal body of a biomarker, compound or body response usable for these medical services |
| Disclaimer with Predetermined Text | "BIOPSY" |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, August 10, 2021 |
| Primary Code | 005 |
| First Use Anywhere Date | Wednesday, January 4, 2023 |
| First Use In Commerce Date | Tuesday, January 24, 2023 |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, August 10, 2021 |
| Primary Code | 044 |
| First Use Anywhere Date | Friday, November 11, 2022 |
| First Use In Commerce Date | Friday, November 11, 2022 |
| Party Name | Earli Inc. |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 03 - Corporation |
| Address | South San Francisco, CA 94080 |
| Party Name | Earli Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | South San Francisco, CA 94080 |
| Party Name | Earli Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | South San Francisco, CA 94080 |
| Event Date | Event Description |
| Tuesday, February 13, 2024 | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| Tuesday, February 13, 2024 | REGISTERED-PRINCIPAL REGISTER |
| Wednesday, January 10, 2024 | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
| Tuesday, January 9, 2024 | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
| Tuesday, January 9, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Tuesday, January 9, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, January 9, 2024 | ASSIGNED TO LIE |
| Tuesday, August 15, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Friday, July 7, 2023 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
| Friday, July 7, 2023 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
| Monday, April 10, 2023 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Monday, April 10, 2023 | NON-FINAL ACTION E-MAILED |
| Monday, April 10, 2023 | SU - NON-FINAL ACTION - WRITTEN |
| Friday, February 24, 2023 | STATEMENT OF USE PROCESSING COMPLETE |
| Wednesday, February 1, 2023 | USE AMENDMENT FILED |
| Thursday, February 23, 2023 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Wednesday, February 1, 2023 | TEAS STATEMENT OF USE RECEIVED |
| Tuesday, September 20, 2022 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Tuesday, July 26, 2022 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, July 26, 2022 | PUBLISHED FOR OPPOSITION |
| Wednesday, July 6, 2022 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Thursday, June 23, 2022 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Friday, May 27, 2022 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Tuesday, May 24, 2022 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, May 24, 2022 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Wednesday, January 19, 2022 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Wednesday, January 19, 2022 | NON-FINAL ACTION E-MAILED |
| Wednesday, January 19, 2022 | NON-FINAL ACTION WRITTEN |
| Thursday, January 13, 2022 | ASSIGNED TO EXAMINER |
| Tuesday, August 10, 2021 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Thursday, May 13, 2021 | NEW APPLICATION ENTERED |